LifeCell Diagnostics announced the inclusion of a new and advanced Lysosomal Screening Disorder screening ‘LSDCheck’ to their newborn screening test menu. With this addition, LifeCell’s newborn screening package becomes one of the most comprehensive and all-encompassing screening packages that parents can opt for their children in India.

Lysosomal storage disorders are a group of approximately 50 rare inherited metabolic conditions that manifest in several ways and vary in severity from moderate to severe. It is crucial to diagnose and manage these conditions as soon as possible before irreversible damage is caused. According to the latest research conducted by the Department of Biochemical and Molecular Genetics in Ahmedabad, 34.8 % of the 1,110 children examined over 10 years met the criteria for a type of Lysosomal Storage Disorder, confirming the disease's extensive prevalence in the country.

LSD screening after birth is highly recommended by medical professionals and doctors across the globe since it reduces the diagnostic odyssey and allows for quick treatment once a diagnosis is made. LifeCell's LSDCheck is a test that uses standardized CE-IVD approved kits that utilize the powerful analytical technique, LCMSMS (Liquid Chromatography with Tandem Mass Spectrometry) based enzyme detection to screen 6 LSD conditions. Hence, LSDCheck comes with the ultimate promise of early diagnosis, as well as access to prompt management and treatment.

Ishaan Khanna, CEO - LifeCell International, said “Lysosomal Storage disorder is a rare disease that affects over 1 in 7,000 people worldwide and this number is considerably higher for a larger Indian population. Keeping this in mind, we have added the LSDCheck to our testing menu for newborns making it one of the most comprehensive screening tests available currently in the market.